纳武利尤单抗治疗晚期黑色素瘤、肾细胞癌或非小细胞肺癌的五年生存及关联因素
该研究为CA209-003Ⅰ期试验的二次分析,纳入270例接受纳武利尤单抗治疗的晚期黑色素瘤、肾细胞癌或非小细胞肺癌患者,中位随访至少58.3个月。估计5年总生存率分别为黑色素瘤34.2%、肾细胞癌27.7%、非小细胞肺癌15.6%。肝或骨转移与5年生存可能性降低独立相关,ECOG评分0与5年生存可能性增加独立相关;出现治疗相关不良事件者总生存显著更长。
要点
- 纳武利尤单抗治疗后估计5年OS率:黑色素瘤34.2%、肾细胞癌27.7%、非小细胞肺癌15.6%。
- 肝转移或骨转移与5年生存可能性降低独立相关,ECOG评分0与5年生存可能性增加独立相关。
- 出现任何级别或≥3级治疗相关不良事件者总生存显著长于无治疗相关不良事件者。
核心结论
- 纳武利尤单抗治疗与部分经重度治疗的晚期黑色素瘤、肾细胞癌或非小细胞肺癌患者的长期生存相关。
- 明确与长期生存相关的因素可能为未来治疗策略和临床试验设计提供参考。
研究设计与样本
- CA209-003Ⅰ期试验(含扩展队列)的二次分析,在美国13个医疗中心开展。
- 纳入2008年10月30日至2011年12月28日入组的270例晚期黑色素瘤、肾细胞癌或非小细胞肺癌患者。
- 患者接受纳武利尤单抗0.1-10.0 mg/kg,每2周一次,8周为一周期,最多96周。
- 总生存为事后终点,最短随访58.3个月。
主要发现
- 270例中黑色素瘤107例(39.6%),肾细胞癌34例(12.6%),非小细胞肺癌129例(47.8%)。
- 估计5年OS率:黑色素瘤34.2%,肾细胞癌27.7%,非小细胞肺癌15.6%。
临床怎么用
- 晚期黑色素瘤、肾细胞癌或非小细胞肺癌患者接受纳武利尤单抗治疗时,部分可获长期生存。
- 肝转移或骨转移提示5年生存可能性较低,ECOG评分0提示5年生存可能性较高。
- 治疗相关不良事件的出现与更长的总生存相关,但需结合安全性管理综合判断。
局限性
- 本研究为Ⅰ期试验的二次分析,总生存为事后终点。
- 样本量有限,各瘤种亚组例数较少。
- 患者为经重度治疗人群,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is approved by the US Food and Drug Administration for treating advanced melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and other malignancies. Data on long-term survival among patients receiving nivolumab are limited. OBJECTIVES: To analyze long-term overall survival (OS) among patients receiving nivolumab and identify clinical and laboratory measures associated with tumor regression and OS. DESIGN, SETTING, AND PARTICIPANTS: This was a secondary analysis of the phase 1 CA209-003 trial (with expansion cohorts), which was conducted at 13 US medical centers and included 270 patients with advanced melanoma, RCC, or NSCLC who received nivolumab and were enrolled between October 30, 2008, and December 28, 2011. The analyses were either specified in the original protocol or included in subsequent protocol amendments that were implemented between 2008 and 2012. Statistical analysis was performed from October 30, 2008, to November 11, 2016. INTERVENTION: In the CA209-003 trial, patients received nivolumab (0.1-10.0 mg/kg) every 2 weeks in 8-week cycles for up to 96 weeks, unless they developed progressive disease, achieved a complete response, experienced unacceptable toxic effects, or withdrew consent. MAIN OUTCOMES AND MEASURES: Safety and activity of nivolumab; OS was a post hoc end point with a minimum follow-up of 58.3 months. RESULTS: Of 270 patients included in this analysis, 107 (39.6%) had melanoma (72 [67.3%] male; median age, 61 [range, 29-85] years), 34 (12.6%) had RCC (26 [76.5%] male; median age, 58 [range, 35-74] years), and 129 (47.8%) had NSCLC (79 [61.2%] male; median age, 65 [range, 38-85] years). Overall survival curves showed estimated 5-year rates of 34.2% among patients with melanoma, 27.7% among patients with RCC, and 15.6% among patients with NSCLC. In a multivariable analysis, the presence of liver (odds ratio [OR], 0.31; 95% CI, 0.12-0.83; P = .02) or bone metastases (OR, 0.31; 95% CI, 0.10-0.93; P = .04) was independently associated with reduced likelihood of survival at 5 years, whereas an Eastern Cooperative Oncology Group performance status of 0 (OR, 2.74; 95% CI, 1.43-5.27; P = .003) was independently associated with an increased likelihood of 5-year survival. Overall survival was significantly longer among patients with treatment-related AEs of any grade (median, 19.8 months; 95% CI, 13.8-26.9 months) or grade 3 or more (median, 20.3 months; 95% CI, 12.5-44.9 months) compared with those without treatment-related AEs (median, 5.8 months; 95% CI, 4.6-7.8 months) (P < .001 for both comparisons based on hazard ratios). CONCLUSIONS AND RELEVANCE: Nivolumab treatment was associated with long-term survival in a subset of heavily pretreated patients with advanced melanoma, RCC, or NSCLC. Characterizing factors associated with long-term survival may inform treatment approaches and strategies for future clinical trial development. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00730639.
引用
- Topalian SL, Hodi FS, Brahmer JR, et al. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol. 2019. PMID: 31343665. doi:10.1001/jamaoncol.2019.2187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。